Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modified factor VIII

A technology for coagulation factor and human coagulation factor, which is applied in the directions of coagulation/fibrinolysis factor, factor VII, blood diseases, etc., and can solve the problems of difficult separation and purification, immunogenicity, insufficient supply of factor VIII, etc.

Inactive Publication Date: 2001-05-30
EMORY UNIVERSITY
View PDF11 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to difficulties in isolation and purification, immunogenicity, and the need to rule out the risk of AIDS and hepatitis infection, factor VIII has been in short supply and has created problems in therapeutic use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified factor VIII
  • Modified factor VIII
  • Modified factor VIII

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 4

[0050] It is shown in Example 4 that a hybrid human / porcine factor VIII, which contains a porcine heavy chain and a human light chain, and corresponds to the Type 1 cross listed above, has better coagulation assays compared to human factor VIII. Strong specific coagulation activity. Hybrid human / animal or equivalent coagulation factor VIII with coagulation activity, whether higher, equal, or lower than human coagulation factor VIII, are useful in the treatment of patients with inhibitory antibodies because these inhibitory antibodies and hybrid human / Animal or equivalent factor VIII response is weaker than human or porcine factor VIII.

[0051] Hybrid factor VIII molecules were prepared by recombination from isolated human and animal factor VIII subunits:

[0052] The present invention provides subunit-substituted hybrid human / animal coagulation factor VIII molecules or fragments thereof, nucleic acid sequences encoding these hybrids, methods of making and isolating them, a...

Embodiment 1

[0160] Example 1: Test of porcine blood coagulation factor VIII and hybrid human / pig coagulation factor VIII

[0161] According to the specific activity of this molecule, porcine coagulation factor VIII has stronger coagulation activity than human coagulation factor VIII. These results are shown in Table III of Example 4. The results were based on the use of appropriate standard curves to allow unbiased comparisons between human and porcine factor VIII. Coagulation tests are based on the ability of coagulation factor VIII to shorten the plasma clotting time in patients with hemophilia A. Two tests were used: primary and secondary tests.

[0162] In a primary test, 0.1 mL of hemophilia A plasma (George King Biomedical, Inc.) and 0.1 mL of activated partial thromboplastin (APTT) (Organon Teknika) were mixed with 0.01 mL of sample or containing diluted Citrated normal human plasma standards were incubated together in a 37°C water bath for 5 minutes. Then add 0.1 ml of 20 mM C...

Embodiment 2

[0165] Example 2: Characterization of functional differences between human and porcine coagulation factor VIII

[0166] The separation of porcine and human plasma-derived coagulation factor VIII and human recombinant coagulation factor VIII is described in literature such as Fulcher, C.A. et al. (1982) Proc.Natl.Acad.Sci.USA 79:1648-1652; Toole et al. (1984) Nature 312: 342-347 (Genetics Institute); Gitschier et al. (1984) Nature 312:326-330 (Genentech); Wood et al. (1984) Nature 312:330-337 (Genentech); Vehar et al., Nature 312:337-342 (Genentech) ; Fass et al. (1982) Blood 59:594; Toole et al. (1986) Proc. Natl. Acad. Sci. USA 83:5939-5942. This can be done in several ways. All of these preparations were similar in subunit composition, despite functional differences in stability between human and porcine factor VIII.

[0167] To compare human recombinant and porcine factor VIII, highly purified human recombinant factor VIII (Cutter Laboratories, Berkeley, CA) and porcine f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Patent Application Serial No. 09 / 037,601, (filed March 10, 1998). [0003] Recognition of Commonwealth Research Support [0004] The government has funded in part the research leading to the present invention through National Institutes of Health grant numbers HL40921, HL46215, and HL36094 and thus has rights in the invention. Background of the invention [0005] The present invention mainly relates to a hybrid coagulation factor VIII, which has the amino acid sequence of human and animal coagulation factor VIII, or has the amino acid sequences of human coagulation factor VIII and non-coagulation factor VIII, and its preparation and use methods. [0006] Blood clotting begins with platelets adhering to the wound wall of injured blood vessels in the area of ​​injury. Then, in a series of enzyme-regulated cascade reactions, soluble fi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K38/00A61K38/37A61K38/43A61K48/00A61P7/04A61P43/00C07H21/04C07K14/755C07K19/00C12N15/11C12N15/12C12P21/02C12R1/91
CPCC07K2319/00C07K14/755A61K38/00A61P43/00A61P7/04C12N15/62
Inventor J·S·洛拉
Owner EMORY UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com